External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology ASN Kidney Week 2023
Roche and Genentech at

ASN Kidney Week 2023

November 02 - November 05
Philadelphia, USA
asn-online.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Nov 4 / Roche and Genentech
Phase III COMMODORE trials of crovalimab▼ in paroxysmal nocturnal hemoglobinuria (PNH): impact on kidney function
Crovalimab▼ was evaluated as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the Phase III COMMODORE 1, 2, and 3 studies. Crovalimab▼ is also being evaluated for atypical hemolytic uremic syndrome (aHUS), a complement-mediated disorder that directly affects the kidneys, in the COMMUTE-a and COMMUTE-p studies. This poster describes an analysis of kidney function in patients from the COMMODORE studies to further assess the feasibility of using crovalimab▼ to treat patients with aHUS.
Haematology Atypical Haemolytic Uraemic Syndrome ASN-Kidney-Week-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 4 / Roche and Genentech
IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy
The aim of the IMAGINATION trial is to evaluate the efficacy, safety and pharmacokinetics of RO7434656 compared with placebo in adults with biopsy-confirmed primary IgA nephropathy (IgAN).
Nephrology Chronic Kidney Disease ASN-Kidney-Week-2023

Sign up or login to unlock the full suite of MEDICALLY features
Nov 2 / Roche and Genentech
Kidney-related outcomes of patients with active lupus nephritis treated with obinutuzumab: a post-hoc analysis of the phase 2 NOBILITY trial
This post hoc analysis evaluated kidney outcomes in patients with lupus nephritis (LN) treated with obinutuzumab in the Phase 2, randomized, double-blind placebo-controlled NOBILITY trial (NCT02550652).
Immunology Systemic Lupus Erythematosus ASN-Kidney-Week-2023
02:00 PM
Duration 2hrs Philadelphia, USA
Baloxavir marboxil▼ (BXM) treatment of influenza in renally impaired patients (pts): post hoc analysis of CAPSTONE-2
Collins C, Cagas SE, Han J, Delporte ML, Retout S
Infectious Disease | Influenza Virus Infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:51 PM
Duration 9mins Philadelphia, PA
Kidney-related outcomes of patients with active lupus nephritis treated with obinutuzumab: a post-hoc analysis of the phase 2 NOBILITY trial
Rovin B, Terres J, Giang S, Schindler T, Turchetta A, Garg J, Furie R, Pendergraft W, Malvar A
Immunology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 2hrs Philadelphia, USA
IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy
Barratt J, Flöge J, Duggal V, Schmit N, Cheng J, Lo J, Rovin BH
Nephrology | Chronic Kidney Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 2hrs Philadelphia, USA
Phase III COMMODORE trials of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH): impact on kidney function
Sreckovic S, Brocchieri C, Leon P, Balachandran N, Ugen M, Buatois S
Haematology | Atypical Haemolytic Uraemic Syndrome

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.